Omega Therapeutics (OMGA) Goldman Sachs 45th Annual Global Healthcare Conference summary

Platform overview and innovation

• Developing programmable mRNA medicines called epigenomic controllers to regulate gene expression at the epigenetic level for disease control.

• Platform enables both gene tuning for disease and cellular reprogramming, with demonstrated durability of response in preclinical models.

• Delivery technologies are a core focus, with internal expertise in LNPs and other modalities for tissue-specific targeting.

• Platform advances apply across all pipeline programs, supporting rapid IND clearance and broad disease applicability.

Novo Nordisk partnership for obesity

• Partnership targets thermogenesis by reprogramming white fat to brown fat using epigenomic controllers, aiming for infrequent dosing and durable effects.

• Financial terms include a $530 million deal value plus royalties, with milestones tied to development progress.

• Delivery to adipose tissue is being co-developed, leveraging advances in nanoparticle technology.

• Regulatory pathway expected to be straightforward due to platform safety profile; endpoints likely to mirror GLP-1 precedents.

• Updates and catalysts will be announced at key milestones in collaboration with Novo.

Oncology pipeline and MYC programs

• OTX-2002 (HCC) and OTX-2101 (NSCLC) target MYC, a gene implicated in a majority of cancers, using liver- and lung-targeted LNPs.

• Phase I dose escalation has established safety and identified efficacious dosing, with expansion to phase II planned.

• Preclinical and early clinical data show strong disease control and potential for both monotherapy and combination regimens.

• Demonstrated synergy with kinase and checkpoint inhibitors, with potential to address post-CPI patient populations.

• Minimal toxicity observed, enabling broad combinatorial use.